var data={"title":"Sodium, potassium, and magnesium sulfates bowel preparation kit: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium, potassium, and magnesium sulfates bowel preparation kit: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/435750?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-potassium-and-magnesium-sulfates-bowel-preparation-kit-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium, potassium, and magnesium sulfates bowel preparation kit: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238875\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Suprep Bowel Prep Kit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238904\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Osmotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239124\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Colon cleansing prior to colonoscopy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Two-day regimen: Total volume of liquid consumed over the course of treatment: 2880 mL (96 oz)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Evening before colonoscopy: Drink the entire contents of 1 bottle, diluted to a final volume of 480 mL (16 oz). Then drink 2 additional containers of water each (filled to the 16-ounce line) over the next hour, for an additional volume of 960 mL (32 oz).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Morning of the colonoscopy (10 to 12 hours after the evening dose): Repeat entire process with the second bottle: Drink entire contents of second bottle diluted to a final volume of 480 mL (16 oz); then drink 2 additional containers of water (each filled to the 16-ounce line) over the next hour, for an additional volume of 960 mL (32 oz). Complete at least 2 hours before the procedure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239125\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560112\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no adjustments provided in the manufacturer's labeling. Use with caution, ensure adequate hydration, and consider baseline and post-colonoscopy renal assessment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560113\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, no adjustment expected due to similar disposition to healthy patients in pharmacokinetic studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11368444\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suprep Bowel Prep Kit: Sodium sulfate 17.5 g, potassium sulfate 3.13 g,  and magnesuim sulfate 1.6 g  per 180 mL (2 x 180 mL) [contains sodium benzoate]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238882\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49345401\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">ColPrep: FDA approved December 2016; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238878\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Suprep: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM222368.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68w6YdzpAwVQ0GS8aM6rBzLg==&amp;TOPIC_ID=16094\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM222368.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239126\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Each bottle of oral solution must be diluted prior to use. The entire contents of each bottle should be consumed, followed by each postdose hydration amount. Patients should avoid red and purple liquids, milk, and alcoholic beverages on the day prior and the day of the colonoscopy. Oral medications should not be administered within 1 hour of start of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Day prior to colonoscopy:</i> Patients may have a light breakfast in the morning; only clear liquids may be consumed the rest of the day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Day of the colonoscopy:</i> Only clear liquids may be consumed; stop drinking clear liquids at least 2 hours before colonoscopy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238905\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Colon cleansing prior to colonoscopy:</b> Cleansing of the colon as a preparation for colonoscopy in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224040\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Suprep Bowel Prep Kit may be confused with Suclear</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239035\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (54%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased uric acid (24%), decreased serum bicarbonate (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (40%), abdominal pain (36%), nausea (36%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercalcemia (10%), electrolyte disturbance (anion gap increased: 9%), fluid and electrolyte disturbance (increased osmolality: 6%; decreased osmolality: 2%), hyponatremia (3%), hyperchloremia (2%), hyperkalemia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (2%), increased serum creatinine (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Atrioventricular block, increased creatine phosphokinase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238909\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sodium sulfate, potassium sulfate, magnesium sulfate, or any component of the formulation; GI obstruction, bowel perforation, gastric retention, ileus, toxic colitis, toxic megacolon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238910\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Serious arrhythmias have occurred rarely with the use of ionic osmotic laxative products; use caution in patients at increased risk for arrhythmias (eg, recent MI, unstable angina, cardiomyopathy, history of prolonged QT, uncontrolled arrhythmias, heart failure); consider baseline and post-colonoscopy ECGs in patients at increased risk for serious arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid and electrolyte abnormalities: May cause fluid and electrolyte disturbances, particularly in patients at increased risk (eg, renal impairment, concomitant mediations that alter electrolyte balance). Any preexisting electrolyte abnormalities should be corrected prior to use and patients should be adequately hydrated before, during, and after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Osmotic laxatives may produce colonic mucosal aphthous ulcerations, including cases of ischemic colitis. Use caution when interpreting colonoscopy results in patients with inflammatory bowel disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia hypocalcemia, hypomagnesemia) and low serum osmolality have occurred. Use with caution in patients with a history of seizures, underlying electrolyte disturbances, in patients at increased risk for seizures (eg, concomitant medications that lower seizure threshold, withdrawal from alcohol or benzodiazepines), or patients with hyponatremia (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: May cause transient increases in uric acid and may precipitate an acute flare; use caution in patients with gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Use with caution in patients with impaired gag reflex and patients prone to regurgitation or aspiration; observe these patients during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; adequate hydration is particularly important in these patients. Consider baseline and post-colonoscopy electrolyte, creatinine, and BUN levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ulcerative colitis: Use with caution in patients with severe, active ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction/perforation (nausea, vomiting, abdominal pain or distension) prior to use. Each bottle must be diluted with water prior to use; inadvertent administration of undiluted solution may increase the risk of nausea, vomiting, and fluid/electrolyte abnormalities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300070\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11304698\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16094&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Magnesium Sulfate may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May enhance the adverse/toxic effect of Magnesium Sulfate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238906\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11238907\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50087734\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if the components of these products are present in breast milk. The manufacturer recommends that caution be exercised when administering to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239108\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;\">Avoid red and purple liquids, milk, and alcoholic beverages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239133\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">Consider baseline and postprocedure electrolytes, BUN, and creatinine in patients at risk for renal impairment, seizure, or who have a history of electrolyte abnormality; ECG (prior to therapy and post-colonoscopy) in patients with risks for prolonged QT or arrhythmias.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239109\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces catharsis by the osmotic effects of the unabsorbed ions in the GI tract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11239111\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Pharmacokinetics measured in terms of serum sulfate unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Sulfate anions poorly absorbed in the GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: 8.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: ~17 hours after first dose; ~5 hours after second dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (primarily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027527\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Suprep Bowel Prep Kit Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.5-3.13-1.6GM/180ML (177 mL): $52.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Colprep (prescribing information). St. Augustine, FL: Gator Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suprep (prescribing information). Braintree, MA: Braintree Laboratories; November 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16094 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F11238875\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F11238904\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F11239124\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F11239125\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22560112\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22560113\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F11368444\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F11238882\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49345401\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11238878\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F11239126\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F11238905\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20224040\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F11239035\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F11238909\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F11238910\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300070\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F11304698\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F11238906\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F11238907\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50087734\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F11239108\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11239133\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11239109\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F11239111\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50027527\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16094|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-potassium-and-magnesium-sulfates-bowel-preparation-kit-patient-drug-information\" class=\"drug drug_patient\">Sodium, potassium, and magnesium sulfates bowel preparation kit: Patient drug information</a></li></ul></div></div>","javascript":null}